Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxycodone/Placebo Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

NCT03415581
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Intranasal Oxycodone, Cue Session
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Opioid Analgesia for MAB

NCT03139240
View directory record Official record
Conditions
MAB, Pain
Interventions
Oxycodone 10mg oral, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Beaverton, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

NCT00560183
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Placebo
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Hydrocodone For Pain Control in First Trimester Surgical Abortion

NCT01330459
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine
Drug
Lead sponsor
Elizabeth Micks
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

NCT00685295
View directory record Official record
Conditions
Pain, Fracture, Sprain
Interventions
Fentanyl, Lansoprazole, Oxycodone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

NCT05447286
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NYX-783, Placebo, Oxycodone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 58 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01358526
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone Controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
151
States / cities
Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

NCT03389750
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 25, 2026, 1:27 AM EDT
Not listed Not applicable Interventional

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

NCT02136784
View directory record Official record
Conditions
Analgesic Response
Interventions
morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Results available

Prescription Medication Interactions

NCT04315181
View directory record Official record
Conditions
Opioid Use, Sedative Use
Interventions
Opioid Agonist, Sedatives
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 1:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study

NCT02692157
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, NT-814 50 mg, NT-814 100 mg, NT-814 200 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

NCT03906721
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burn Injury, Pain Management
Interventions
Placebo, Oxycodone, Essential Oil
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

NCT01780428
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977
View directory record Official record
Conditions
Osteoarthritis
Interventions
Oxycodone, Placebo, PF-000592379
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

NCT01395784
View directory record Official record
Conditions
Opioid Abuse
Interventions
pioglitazone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 4 Interventional Results available

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

NCT00414453
View directory record Official record
Conditions
Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions
Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

NCT00315445
View directory record Official record
Conditions
Back Pain
Interventions
Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

NCT00613938
View directory record Official record
Conditions
Arthralgia, Bunion, Hallux Valgus, Pain
Interventions
Tapentadol (CG5503), oxycodone, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 25, 2026, 1:27 AM EDT